The biotech’s double-digit plunge was mainly sparked by its worse-than-expected 2017 guidance that was released late Tuesday. The key piece of information that’s driving Gilead’s shares lower on Wednesday is the biotech’s particularly anemic 2017 sales forecast for its hepatitis C franchise.